AFX:XETRCarl Zeiss Meditec AG Analysis

Carl Zeiss Meditec AG (AFX) is trading around €25, notably above its DCF‑derived fair value of €6.78, indicating a substantial premium. The stock sits below its 20‑day (≈€25.96) and 50‑day (≈€26.17) SMAs, and the MACD histogram is negative, reinforcing a bearish technical backdrop. Recent earnings releases highlighted a 5.7% YoY revenue decline to €991 million and an adjusted EBITDA margin drop to 6.1%, with the share price slipping ~3% after the miss. Despite these pressures, the company maintains a respectable dividend yield of 2.22% and a modest payout ratio of 44%, supported by €88 million of free cash flow. Its forward P/E of ~13.4 is well below the industry average of 24.8, suggesting relative valuation appeal on a peer basis. However, high 30‑day volatility (≈55%) and a recent earnings disappointment temper enthusiasm.
The balance sheet shows €580 million of debt versus €24 million of cash, yielding a debt‑to‑equity of ~28%—manageable but warranting monitoring. Low systematic risk (beta ≈0.13) and stable trading volumes mitigate liquidity concerns, while regulatory and geographic exposures remain medium due to the medical‑device landscape and diversified global operations. In summary, the stock appears over‑priced relative to intrinsic models, bears short‑term downside risks, yet offers dividend income and a potential value edge versus peers.